Key Takeaways
- • BioCentury announced that the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) will serve as Regional Host Chair of the 6th BioCentury-BayHelix East-West Biopharma Summit, scheduled for March 15-17, 2027, at the Conrad Seoul.
- • KPBMA, whose membership is about 300 Korean pharmaceutical and biotech companies, is chaired at the Regional Host Committee level by KPBMA President Yunhong Noh, with executives from ABL Bio, Alteogen, CHA Biotech, Ildong Pharmaceutical, KB Investments, LG Chem, and SK Biopharmaceuticals participating.
- • The summit is presented by BioCentury, BayHelix, and Insights Partner McKinsey & Company, and returns to Seoul for the second time with a focus on cross-border licensing, NewCo creation, and clinical and manufacturing capabilities across Asia.
- • Registration is open, and biotechs from Korea, Asia, and the West can apply for the Presenting Company Class of 2027; sponsorship opportunities are also available.
Summary
BioCentury announced that the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) will serve as Regional Host Chair of the 6th BioCentury-BayHelix East-West Biopharma Summit, taking place March 15-17, 2027, at the Conrad Seoul in South Korea. The summit is presented by BioCentury, BayHelix, and Insights Partner McKinsey & Company, and returns to Seoul for the second time to continue its discussion of Asia's Arc of Innovation. According to the announcement, KPBMA will help connect Korea's biopharma leaders with investors and dealmakers from across Asia and the West.
David Flores, Co-Founder, President and CEO of BioCentury, said the Seoul location reflects the active role Korean companies play in cross-border dealmaking, citing their science, clinical expertise and manufacturing capacity. KPBMA President Yunhong Noh chairs the summit's Regional Host Committee, which includes senior leaders from ABL Bio, Alteogen, CHA Biotech, Ildong Pharmaceutical, KB Investments, the Korea Health Industry Development Institute, LG Chem and SK Biopharmaceuticals. The committee works with the summit's International Steering Committee to build a program around Korea's growing role as a source of first-in-class innovation and a destination for clinical trials and biomanufacturing. Noh said the event would help Korean members reach global investors and partners, and that it would catalyze new cross-border partnerships.
The summit targets C-level executives, venture capital and private equity investors, biotech CEOs, CFOs, chief business officers, and business development and licensing leaders from Australia, China, India, Japan, Singapore, South Korea, Southeast Asia and the West. Planned sessions cover faster clinical data generation by Asian biotechs, sourcing of Asia-originated assets, the most compelling assets for licensing and NewCo creation, Asia-based contract development and manufacturing providers, and licensing opportunities across Korea, Japan, Singapore and Australia.
The program includes an ecosystem tour on the morning of March 15, an overnight excursion on March 17-18 to Songdo, home to Samsung Biologics, Celltrion and Lotte Biologics, and an exclusive CEO and Investor Reception on March 15. Space is limited, and early registration is encouraged. Registration is open, and biotechs from Korea, Asia and the West may apply to join the Presenting Company Class of 2027. Sponsorship opportunities are also available for organizations interested in thought leadership and branding.
David Flores, Co-Founder, President and CEO of BioCentury, said the Seoul location reflects the active role Korean companies play in cross-border dealmaking, citing their science, clinical expertise and manufacturing capacity. KPBMA President Yunhong Noh chairs the summit's Regional Host Committee, which includes senior leaders from ABL Bio, Alteogen, CHA Biotech, Ildong Pharmaceutical, KB Investments, the Korea Health Industry Development Institute, LG Chem and SK Biopharmaceuticals. The committee works with the summit's International Steering Committee to build a program around Korea's growing role as a source of first-in-class innovation and a destination for clinical trials and biomanufacturing. Noh said the event would help Korean members reach global investors and partners, and that it would catalyze new cross-border partnerships.
The summit targets C-level executives, venture capital and private equity investors, biotech CEOs, CFOs, chief business officers, and business development and licensing leaders from Australia, China, India, Japan, Singapore, South Korea, Southeast Asia and the West. Planned sessions cover faster clinical data generation by Asian biotechs, sourcing of Asia-originated assets, the most compelling assets for licensing and NewCo creation, Asia-based contract development and manufacturing providers, and licensing opportunities across Korea, Japan, Singapore and Australia.
The program includes an ecosystem tour on the morning of March 15, an overnight excursion on March 17-18 to Songdo, home to Samsung Biologics, Celltrion and Lotte Biologics, and an exclusive CEO and Investor Reception on March 15. Space is limited, and early registration is encouraged. Registration is open, and biotechs from Korea, Asia and the West may apply to join the Presenting Company Class of 2027. Sponsorship opportunities are also available for organizations interested in thought leadership and branding.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.